Journals / Turkish Journal of Chemistry / 2004 / Cilt: 28 - Sayı: 6

Synthesis and antitumor activities of some new 4-(1-naphthylmethylamino)-and 4-(1-naphtylmethylamino)-1,2,4-triazol-5-one derivatives

Pages
679–690
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The in vitro antitumor activities of some selected compounds were screened and compounds 3e, 5c, 6e and 9c were found to be active.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A series of 4-(1-naphthylidenamino)-1,2,4-triazol-5-one derivatives (3a-e) were synthesized by condensation of corresponding 3-alkyl-4-amino-4,5-dihydro-1H-1,2,4-triazol-5-ones with 1-naphthaldehyde.
📊
Key Findings & Data:Acetylation and alkylation of these compounds gave 4a-e and 5a-e, respectively.
💡
Conclusion & Impact:The in vitro antitumor activities of some selected compounds were screened and compounds 3e, 5c, 6e and 9c were found to be active.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

A series of 4-(1-naphthylidenamino)-1,2,4-triazol-5-one derivatives (3a-e) were synthesized by condensation of corresponding 3-alkyl-4-amino-4,5-dihydro-1H-1,2,4-triazol-5-ones with 1-naphthaldehyde. Acetylation and alkylation of these compounds gave 4a-e and 5a-e, respectively. Sodium borohydride reduction of 1-naphthylidenamino derivatives afforded naphthylmethylamino derivatives, which were sub-sequently acetylated. Depending on the duration of the acetylation, mono or bis acetamide derivatives were obtained. The in vitro antitumor activities of some selected compounds were screened and compounds 3e, 5c, 6e and 9c were found to be active.

🔖

Cite This Article

DEMİRBAŞ, N., UĞURLUOĞLU, R. (2022). Synthesis and antitumor activities of some new 4-(1-naphthylmethylamino)-and 4-(1-naphtylmethylamino)-1,2,4-triazol-5-one derivatives. Turkish Journal of Chemistry, Cilt: 28 - Sayı: 6, 679–690. https://ajindex.com/articles/602241

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (20)

  1. Ş. Demirayak, K. Benkli and K. Güven, Eur. J. Med. Chem., 35, 1037-40 (2000)
  2. A. Demirbaş, C.B. Johansson, N. Duman and A.A. İkizler, Acta Pol. Pharm.-Drug Res., 53, 117-21 (1996)
  3. A.A. İkizler, F. Uçar, N. Demirbaş, I. Yasa, A. Demirbaş and T. Genzer, Ind. J. Pharm. Sci., 61, 271-74 (1999)
  4. H. Yüksek, A. Demirbaş, A. İkizler, C.B. Johansson, C. Çelik and A.A. İkizler, Arzn.- Forsh. Drug Res.,47, 405-9 (1997)
  5. G. Turan-Zitouni, M.F. Sıvacı, S. Kılıç and K. Erol, Eur. J. Med. Chem., 36, 685-89 (2001)
  6. A.A. İkizler, E. Uzunali and A. Demirbaş, Indian J. Pharm., 5, 289-92 (2000)
  7. N. Demirbaş, R. Ugurluoglu and A. Demirbaş, Bioorg. Med. Chem., 10, 3717-21 (2002)
  8. R.N. Feinstein, R. J. Fry and E.F. Staffeld, J. National Cancer Inst., 60, 1113-16 (1978)
  9. B.S. Holla, K.N. Poorjary, B.S. Tao and M.K. Shivananda, Eur. J. Med. Chem., 37, 511-17 (2002)
  10. B.S. Holla, B.K. Sarojini, B.S. Rao, P.M. Akberali, N.S. Kumari and V. Shatty, Il Farmaco, 56, 565-70 (2001)
  11. B.K. Keppler, W. Balzer and V. Seifried, Arzn.-Forsch., 37, 770-71 (1987)
  12. N. Demirbaş, S. Alpay Karaoğlu, A. Demirbaş and K. Sancak, Eur. J. Med. Chem., 39, 793-804 (2004)
  13. P.E. Goss and K. Strasser-Weippl, Best Pract. Res. Clin. End. Met., 18, 113-30 (2004)
  14. J. R. Santen, Steroids, 68, 559-67 (2003)
  15. M. Clemons, R.E. Coleman and S. Verma, Cancer Treat. Rew., 30, 325-32 (2004)
  16. S.Chen, Y.C. Kao and C. A. Laughton, J. Steroid Biochem., 61, 107-15 (1997)
  17. A.A. İkizler and R. Ün, Chem. Acta Turc., 7, 269-90 (1979)
  18. B. Kahveci and A.A. İkizler, Turk. J. Chem., 24, 343-51 (2000)
  19. J. Daunis, Y. Quindo, R. Jacquer and P. Vialefont, Bull. Soc. Chim. France, 3296-99 (1971)
  20. G.D. Gray and E. Wickstrom, Biotechniques, 21, 780-82 (1996).